Péter Lichter - Genetic Mutations

Author Information

Peter Lichter is affiliated with the Division of Molecular Genetics at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. His research primarily focuses on the genetic and molecular basis of cancer, with an emphasis on understanding tumor biology, precision oncology, and the role of genetic mutations in cancer progression.

Research Contributions

Peter Lichter has made significant contributions to the field of cancer genetics and genomics. His recent work includes studies on the synergistic effects of HDAC- and PARP inhibitors in childhood tumors with chromothripsis, the association of mutation signatures with mutation hotspots in driver genes, and the use of cell-based interceptive medicine to improve European healthcare. Additionally, his research on the antitumor activity of T regulatory cells, clonal genome evolution in cancer, and precision oncology trials in metastatic breast cancer highlights his dedication to advancing cancer treatment and understanding the molecular underpinnings of the disease.

Aliases

Peter Lichter is also known by the following aliases: P Lichter, P. Lichter, and Péter Lichter.

Publication and Citation Metrics

Metric	Value
Citation Count	82,979
H-Index	135
Paper Count	853

Publications:

A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis.

DOI: 10.1002/ijc.34027

Year: 2022

Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions

DOI: 10.1038/s41467-021-27792-6

Year: 2022

Publisher Correction: LifeTime and improving European healthcare through cell-based interceptive medicine

DOI: 10.1038/s41586-021-03287-8

Year: 2021

CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer

DOI: 10.1200/PO.20.00248

Year: 2021

EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia

DOI: 10.1038/s41375-021-01136-1

Year: 2021

Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion

DOI: 10.1101/2021.05.11.443369

Year: 2021

Time-resolved, integrated analysis of clonal genome evolution in parthenogenetic animals and in cancer

DOI: 10.1101/2021.10.08.463633

Year: 2021

Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity.

DOI: 10.1016/j.immuni.2021.11.004

Year: 2021

Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy

DOI: 10.3324/haematol.2020.265777

Year: 2021

The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets.

DOI: 10.1158/2159-8290.CD-21-0094

Year: 2021

How Does Asbestos Lead to Genetic Mutations?

Why is Third Generation Sequencing Important for Genetic Mutations?

What are Deletions?

What are the Challenges Ahead?

What Are the Challenges of Gene Therapy?

What is the Future of Hemoglobin Electrophoresis?

What are DNA Molecules?

How is Hemophilia Inherited?

Can Genetic Disorders Affect Child Development?

How Do These Mutagens Affect DNA?

Partnered Content Networks

Relevant Topics